The DOI matches its Crossref record; the references it cites are not checked yet.
LBA84 Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)
Open accessOverview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the ENZA-p trial, [177Lu]Lu-PSMA-617 in addition to enzalutamide demonstrated significantly improved PSA-based outcomes in high-risk, first-line mCRPC versus enzalutamide alone.
“The value of PSMA-RLT in addition to an ARPI was assessed in the ENZA-p (NCT04419402) trial, which demonstrated significantly improved PSA-based outcomes in high-risk, first-line mCRPC vs enzalutamide alone, suggesting future larger studies should evaluate combination approaches [84].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [84]
Citations
The citation lists haven’t been fetched yet
Cited by 12
Metadata
- Authors
- Emmett, L., Subramaniam, S., Crumbaker, M., Joshua, A. M., Weickhardt, A. J., Lee, S. T., Ng, S., Francis, R. J., Goh, J. C. H., Pattison, D. A., Tan, H., Kirkwood, I. D., Sandhu, S. K., Nguyen, A., Gedye, C., Rutherford, N., Hofman, M., Martin, A., Stockler, M. R., & Davis, I. D.
- Affiliations
- St Vincent's Hospital Sydney (AU)
- The University of Sydney (AU)
- The Kinghorn Cancer Centre (AU)
- Austin Health (AU)
- Austin Hospital (AU)
- Sir Charles Gairdner Hospital (AU)
- The University of Western Australia (AU)
- Royal Brisbane and Women's Hospital (AU)
- Royal Adelaide Hospital (AU)
- Peter MacCallum Cancer Centre (AU)
- Calvary Mater Newcastle Hospital (AU)
- Hunter New England Local Health District (AU)
- Victorian Comprehensive Cancer Centre (AU)
- Eastern Health (AU)
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2023-10
- Volume
- 34
- Pages
- S1325
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W4387809611
- Cited by
- 12
- References
- 0
- Citations by year
- 2025: 2 · 2024: 8 · 2023: 2
- Type
- conference abstract
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Keywords
- enzalutamide, 177Lu-PSMA-617, castration-resistant prostate cancer, metastatic prostate cancer, androgen receptor pathway inhibitors, combination therapy, adaptive dosing, first-line therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
